Relative to aging and chronic disease policy.
SR 104 is a Senate resolution expressing support for a policy approach that targets the biological processes of aging as a way to prevent or delay chronic disease. The resolution frames aging as the underlying driver of many major illnesses, including heart disease, cancer, stroke, diabetes, Alzheimer’s disease, respiratory disease, and kidney disorders, and argues that extending health span is more important than simply extending lifespan. It also emphasizes the growing fiscal and public health burden of chronic disease on Californians, health systems, families, employers, and the state budget.
The resolution urges California to invest in research grants, public-private partnerships, and regulatory frameworks that would support therapies intended to slow, prevent, or reverse aspects of biological aging. It also encourages the State Department of Public Health and the California Department of Aging to incorporate aging science into chronic disease prevention and healthy aging programs, including education, outreach, and demonstration projects. In addition, it calls for collaboration among academic institutions, health plans, and biotechnology firms to pilot aging interventions and reduce long-term care costs.
As a resolution, SR 104 does not change statutory law or create enforceable rights or obligations. Its practical effect is to express the Senate’s policy position and to encourage state agencies, researchers, and industry partners to prioritize aging biology in chronic disease prevention and healthy aging efforts. The resolution is aimed at influencing future funding, program design, and regulatory development rather than amending the Health and Safety Code, Welfare and Institutions Code, or other statutes.
The available record shows strong support and no recorded opposition: the Senate adopted the resolution unanimously, 36-0. The tone of the measure is affirmative and aspirational, presenting aging research and longevity medicine as promising tools for improving health outcomes and reducing costs. The absence of committee transcript debate suggests the bill moved without notable public controversy in the available materials.
No specific points of contention appear in the provided record, and there were no recorded no votes. Potential areas of policy debate implied by the resolution include whether the state should direct resources toward aging biology and longevity interventions, how much public funding should support this research, and whether regulatory frameworks should be adapted for therapies that target aging itself. The resolution’s emphasis on biotechnology partnerships and “longevity medicines” could also raise questions for some stakeholders about scientific readiness, oversight, and prioritization relative to other public health needs.